Monthly Archive

Monthly Archives: March 2012

March 21, 2012 no comments

Five Vital Statistics of a Successful Venture Fund – How does the new Index Ventures Life Science Fund Measure up?

The launch of Index Ventures’ new life sciences fund on March 21st is another big step in the reincarnation of the biotech investment model.  As a smaller, focused fund it will carry even further the “asset-centric” strategy Index have championed.  But the most obvious new feature is the inclusion of two global pharmaceutical giants as strategic investors in the fund.

It is, therefore, a very different beast from most venture capital funds, particularly in the US.  Different doesn’t always mean better, so DrugBaron asks what would be the optimal parameters for a life sciences fund to have in 2012, and measures this new entrant against that yardstick


March 13, 2012 no comments

Drugging the apolioprotein E pathway – the starters gun has sounded

It can take years or even decades to properly

Read More
March 1, 2012 no comments

Combinatorial animal study designs

It is sometimes assumed that government reg

Read More

Monthly Archive